pharma · Hypoparathyroidism (HP) in Adults · Chronic hypoparathyroidism
Ascendis Pharma
Ascendis Pharma Bone Diseases A/S
Ascendis Pharma patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 3
- Patents
- 12
Ascendis Pharma patents
12 pharmaceutical patents indexed for Ascendis Pharma. 0 expire within 24 months.
Ascendis Pharma has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
WO 2025051711
TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE
granted -
WO 2024094673
RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH
granted -
US 2023321198
Dosage Regimen for a Controlled-Release PTH Compound
granted -
CA 3230895
TRAITEMENTS AVEC DES COMPOSES PTH A ACTION PROLONGEE
granted -
CA 3192772
AMELIORATION DU BIEN-ETRE PHYSIQUE ET MENTAL DE PATIENTS ATTEINTS D'HYPOPARATHYROIDISME
granted -
CA 3161101
TRAITEMENT DE L'HYPOPARATHYROIDISME
granted -
US 2020276276
PTH Prodrugs
granted -
CA 3129357
FORMULATIONS PHARMACEUTIQUES LIQUIDES DE CONJUGUES PTH
granted -
CA 3099620
DOSE INITIALE DE CONJUGUES DE LA PTH
granted -
US 2019282668
PTH Compounds with Low Peak-To-Trough Ratios
granted -
MA 46343
SCHÉMA POSOLOGIQUE POUR UN COMPOSÉ DE PTH À LIBÉRATION CONTRÔLÉE
granted -
US 2019224329
Incremental Dose Finding in Controlled-Release PTH Compounds
granted
Frequently asked questions
How many patents does Ascendis Pharma have?
12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Ascendis Pharma patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.